UnknownNot Applicable

Bipolar Hemostatic Forceps Versus Standard Therapy in Acute Non-variceal Upper GI Bleeding

Germany80 participantsStarted 2023-01-01

Plain-language summary

Bipolar hemostatic forceps will be tested against standard therapy in active, non-variceal, upper gastrointestinal bleeding by a prospective, randomized trial

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Active, nonvariceal, upper gastrointestinal bleeding Exclusion Criteria: * Severe coagulopathy unresponsive to blood products transfusions: platelets \<20,000; international normalized ratio \>3.0; partial thromboplastin time \>2 normal

What they're measuring

Successful primary hemostasis

Timeframe: 15 minutes

Rebleeding

Timeframe: 30 days

Trial details

NCT IDNCT05353062

SponsorTheresienkrankenhaus und St. Hedwig-Klinik GmbH

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-01

Contact for this trial

Daniel Schmitz, MD

+491758674415 Daniel.Schmitz@helios-gesundheit.de

View on ClinicalTrials.gov More Gastrointestinal Hemorrhage trials